v3.26.1
Description of Business and Basis of Presentation (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Feb. 28, 2026
Jan. 30, 2026
Dec. 31, 2025
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Cash and cash equivalents $ 98,086     $ 88,932
Accumulated deficit $ 302,558     $ 326,692
vTv Therapeutics LLC        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC 100.00%      
Newsoara Biopharma Co Ltd | Collaborative Arrangements        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
License fee received   $ 20,000 $ 20,000  
Parent Company        
Organization Consolidation And Presentation Of Financial Statements [Line Items]        
Cash and cash equivalents $ 78,000